Safety and tolerability of an intra-seasonal initiation of the sq-standardised grass allergy immunotherapy tablet: A non-interventional observational study investigating the feasibility during routine administration

Clinical Drug Investigation

Volumn 33, Issue 10, 2013, Pages 719-726

  Schwab, Jan Alexander ^a   Wolf, Hendrik ^b   Schnitker, Jörg ^c   Wüstenberg, Eike ^b,d  

^a Schwab Schwab Interdisciplinary Therapy Center   (Germany)

^b ALK SCHERAX Arzneimittel GmbH   (Germany)

^c Institut für Angewandte Statistik IAS   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GRASS POLLEN VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR PRURITUS; FEMALE; GERMANY; GRASS POLLEN; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; ORAL PARESTHESIA; ORAL PRURITUS; PATIENT COMPLIANCE; PATIENT SATISFACTION; POLLEN ALLERGY; PRIORITY JOURNAL; SEASONAL VARIATION; TABLET; THROAT IRRITATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DESENSITIZATION, IMMUNOLOGIC; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; POACEAE; PROSPECTIVE STUDIES; PRURITUS; RHINITIS, ALLERGIC, SEASONAL; SEASONS; TABLETS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885135110     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0115-8     Document Type: Article

References (20)

1. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GALEN and Aller-Gen). Allergy. 2008;63(Suppl 86):8-160.
2. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004;24(5):758-64.
3. European Medicines Agency. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. November 2008. Publication no. CHMP/EWP/18504/2006. http://www.ema.europa.eu/ docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003605.pdf Accessed 22 Jul 2013.
4. Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization position paper 2009. Allergy. 2009;64(Suppl 91):1-59.
5. Cox L. Safety implications of different administration routes for specific immunotherapy [abstract]. J Allergy Clin Immunol. 2010; 125(2 Suppl 1): AB35.
6. Malling HJ, Lund L, Ipsen H, Poulsen L. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets. J Investig Allergol Clin Immunol. 2006;16(3):162-8.
7. Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebocontrolled trial. Allergy. 2006;61(2):181-4.
8. Calderon M, Essendrop M. Specific immunotherapy with high dose SQ standardised grass allergen tablets was safe and well tolerated. J Investig Allergol Clin Immunol. 2006;16(6):338-44.
9. Ibañez MD, Kaiser F, Knecht R, et al. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children. Pediatr Allergy Immunol. 2007;18(6):516-22.
10. Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117(4):802-9.
11. Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablet for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;118(2):434-40.
12. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy. 2006;61(2):185-90.
13. Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol. 2009;123(1):167-73.
14. Dahl R, Kapp A, Colombo G, et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol. 2008;121(2):512-8.
15. Durham SR, Emminger W, Kapp A, et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol. 2010;125(1):131-8.
16. Durham SR, Emminger W, Kapp A, de Monchy JGR, Rak S, Scadding G, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129(3):717-25.
17. Reich K, Gessner C, Kroker A, Schwab JA, Pohl W, Villesen H, Wüstenberg E, Emminger W. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis. Clin Ther. 2011;33(7):828-40.
18. ® (75,000 SQ-T oral lyophilisate) [summary of product characteristics]. Wedel: ALK; 30 Oct 2009.
19. Calderon MA, Birk AO, Andersen JS, Durham SR. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy. Allergy. 2007;62(8):958-61.
20. Shamji MH, Ljørring C, Francis JN, et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy. 2012;67(2):217-26.